{"id":"nicergoline","rwe":[{"pmid":"41467376","year":"2025","title":"Use of nootropics in Alzheimer's disease: An analysis of regulatory positions and drug policies in the countries of the Commonwealth of Independent States.","finding":"","journal":"The International journal of risk & safety in medicine","studyType":"Clinical Study"},{"pmid":"41352917","year":"2026","title":"Development and validation of UPLC-MS/MS method for detecting nootropic misuse in oral fluids: A step towards combating doping in Esports.","finding":"","journal":"Analytica chimica acta","studyType":"Clinical Study"},{"pmid":"41155580","year":"2025","title":"Controlled Crystallization Enables Facile Fine-Tuning of Physical-Chemical Properties of Nicergoline Toward Easier Processability.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41155541","year":"2025","title":"α(1A)-Adrenergic Receptor as a Target for Neurocognition: Cautionary Tale from Nicergoline and Quinazoline Non-Selective Blockers.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"40871038","year":"2025","title":"Development and Preclinical Evaluation of Fixed-Dose Capsules Containing Nicergoline, Piracetam, and Hawthorn Extract for Sensorineural Hearing Loss.","finding":"","journal":"Pharmaceutics","studyType":"Clinical Study"}],"tags":[{"label":"nicergoline","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C04AE02","category":"atc"},{"label":"Active","category":"status"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Antagonists","category":"pharmacology"},{"label":"Adrenergic alpha-Antagonists","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Nootropic Agents","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"discontinued","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"cergodum","offLabel":[],"synonyms":["nicergoline","nicergolent","nicotergoline","cergodum","duracebrol"],"timeline":[],"approvals":[],"brandName":"Cergodum","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"nicergoline","explanation":"Imagine your brain is a garden, and blood flow is like water nourishing the plants. Nicergoline helps to improve the flow of this water, allowing the brain to function better and potentially improving symptoms of certain conditions.","oneSentence":"Nicergoline works by increasing blood flow to the brain and improving cognitive function.","technicalDetail":"Nicergoline acts as a selective alpha-1 adrenergic receptor agonist and a serotonin receptor agonist, which leads to vasodilation and increased cerebral blood flow."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1910","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NICERGOLINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NICERGOLINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:56:35.916562","biosimilars":[],"competitors":[{"drugName":"ergoloid mesylates","drugSlug":"ergoloid-mesylates","fdaApproval":"1953-11-05","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"nicergoline","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"ergoloid-mesylates","brandName":"ergoloid mesylates","genericName":"ergoloid mesylates","approvalYear":"1953","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05551182","phase":"PHASE3","title":"Nicergoline Use in Dysphagia Patients","status":"COMPLETED","sponsor":"Phramongkutklao College of Medicine and Hospital","startDate":"2023-01-01","conditions":["Dysphagia"],"enrollment":92,"completionDate":"2025-08-20"},{"nctId":"NCT07166835","phase":"NA","title":"Exploring the Cognitive Benefits of a Blackcurrant-Based Supplement in Normobaric Hypoxia","status":"NOT_YET_RECRUITING","sponsor":"Leeds Beckett University","startDate":"2025-09-01","conditions":["Cognitive Performance","Executive Function (Cognition)","Working Memory","Hypoxia Induced Cognitive Impairment","Mood"],"enrollment":27,"completionDate":"2027-10-01"},{"nctId":"NCT06689644","phase":"NA","title":"Effect of a Plant Based Nootropic on Perceptual Decision Making.","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2023-10-23","conditions":["Cognitive Enhancement"],"enrollment":37,"completionDate":"2024-06-01"},{"nctId":"NCT04176367","phase":"PHASE1","title":"An Bioequivalence Study Comparing Nicergoline 10 mg Tablet Manufactured in China With Nicergoline 10 mg Tablet Manufactured in Italy Under Fasted and Fed Conditions in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2019-12-17","conditions":["Pharmacokinetics"],"enrollment":40,"completionDate":"2020-09-29"},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":["Dementia","Depression","Schizophrenia","Psychosomatic Disorders","Anxiety Disorders"],"enrollment":407,"completionDate":"2017-06-28"},{"nctId":"NCT01009476","phase":"","title":"Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2006-03","conditions":["Dementia","Alzheimer Disease","Dementia, Vascular"],"enrollment":1134,"completionDate":"2008-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000167295","NDDF":"004170","UNII":"JCV8365FWN","CHEBI":"CHEBI:31902","INN_ID":"3088","RXNORM":"7398","UMLSCUI":"C0028008","ChEMBL_ID":"CHEMBL1372950","KEGG_DRUG":"D01290","DRUGBANK_ID":"DB00699","PUBCHEM_CID":"34040","SNOMEDCT_US":"698197004","MESH_DESCRIPTOR_UI":"D009530"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"5%"},"publicationCount":417,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"C04AE02","allCodes":["C04AE02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Dec 30","pmid":"41467376","title":"Use of nootropics in Alzheimer's disease: An analysis of regulatory positions and drug policies in the countries of the Commonwealth of Independent States.","journal":"The International journal of risk & safety in medicine"},{"date":"2026 Jan 15","pmid":"41352917","title":"Development and validation of UPLC-MS/MS method for detecting nootropic misuse in oral fluids: A step towards combating doping in Esports.","journal":"Analytica chimica acta"},{"date":"2025 Sep 29","pmid":"41155580","title":"Controlled Crystallization Enables Facile Fine-Tuning of Physical-Chemical Properties of Nicergoline Toward Easier Processability.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2025 Sep 23","pmid":"41155541","title":"α(1A)-Adrenergic Receptor as a Target for Neurocognition: Cautionary Tale from Nicergoline and Quinazoline Non-Selective Blockers.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2025 Aug 5","pmid":"40871038","title":"Development and Preclinical Evaluation of Fixed-Dose Capsules Containing Nicergoline, Piracetam, and Hawthorn Extract for Sensorineural Hearing Loss.","journal":"Pharmaceutics"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cergodum, also known as Nicergoline, is a small molecule drug in the nicergoline class. It is used to treat certain conditions, although its exact target is unknown. The commercial status of Cergodum is unclear, and it may be patented or have generic manufacturers. Key safety considerations are not well-documented. Further research is needed to fully understand its effects and risks.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}